THE USE OF MOLECULAR-GENETIC TESTING TO CONFIRM THE DIAGNOSIS OF PRIMARY-MULTIPLE LUNG CANCER (PMLC): A DESCRIPTION OF THE CLINICAL CASE

EXPERIENCE OF ONCOLOGY CLINICS

https://doi.org/10.37469/0507-3758-2017-63-4-655-656

Published 01.04.2017

Andrey Nefedov⁺⁻
Vladislav Tyurin⁺⁻
Yevgeniy Imyanitov⁺⁻
Natalya Mityushkina⁺⁻

Andrey Nefedov

St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)

Vladislav Tyurin

St. Petersburg State Pediatric Medical University, N.N. Petrov Research Institute of Oncology

Yevgeniy Imyanitov

St. Petersburg State Pediatric Medical University, N.N. Petrov Research Institute of Oncology, I.I. Mechnikov North-West State Medical University

Natalya Mityushkina

N.N. Petrov Research Institute of Oncology

##article.numberofdownloads## 22

##article.numberofviews## 464

PDF (Русский)

Keywords

LUNG CANCER
KRAS
PRIMARY-MULTIPLE CANCER

How to Cite

Nefedov, A., Tyurin, V., Imyanitov, Y., & Mityushkina, N. (2017). THE USE OF MOLECULAR-GENETIC TESTING TO CONFIRM THE DIAGNOSIS OF PRIMARY-MULTIPLE LUNG CANCER (PMLC): A DESCRIPTION OF THE CLINICAL CASE. Voprosy Onkologii, 63(4), 655–656. https://doi.org/10.37469/0507-3758-2017-63-4-655-656

Abstract

This article describes a case of synchronous bilateral lung cancer, which was diagnosed with the use of molecular-ge-netics testing. Identification of two distinct KRAS mutations in tumors of right and left lungs supported independent origin of these neoplasms.

https://doi.org/10.37469/0507-3758-2017-63-4-655-656

##article.numberofdownloads## 22

##article.numberofviews## 464

PDF (Русский)

References

Моисеенко В.М., Проценко С.А., Семенов И.И. и др. Применение Ирессы (гефитиниба) в качестве терапии первой линии для лечения неоперабельных аденокарцином лёгкого, содержащих мутацию в гене EGFR//Современная онкология. -2010. -Т. 12. -№ 1. -С. 74-80.

Imyanitov E.N., Demidova I.A., Gordiev M.G. et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer//Mol. Diagn. Ther. -2016. -Vol. 20 (4). -p 401-406.

Korpanty G.J., Graham D.M., Vincent M.D., Leighl N.B. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS//Front. Oncol. -2014. -Vol. 4. -P. 204.

Kris M.G., Johnson B.E., Berry L.D. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs//JAMA. -2014. -Vol. 311 (19). -P. 1998-2006.

Nakano H., Soda H., Nakamura Y et al. Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers//Clin. Lung Cancer. -2007. -Vol. 8 (9). -P. 562-564.

Takamochi K., Oh S., Matsuoka J., Suzuki K. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras//Lung Cancer. -2012. -Vol. 75 (3). -P 313-320.

Xue X., Liu Y, Pan L. et al. Diagnosis of multiple primary lung cancer: a systematic review//J. Int. Med. Res. -2013. -Vol. 41 (6). -P 1779-1787.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.